Erturk, IsmailSaglam, KenanElasan, SadiAykan, Musa B.Acar, RamazanYesildal, FatihOzgurtas, Taner2025-05-102025-05-1020180379-528410.15537/smj.2018.10.229462-s2.0-85054440459https://doi.org/10.15537/smj.2018.10.22946https://hdl.handle.net/20.500.14720/15956Saglam, Kenan/0000-0003-2543-8853; Yesildal, Fatih/0000-0002-8738-5964Objectives: To investigate the clinical significance of VEGF, sVEGFR-1 in heart failure reduced ejection fraction (HFrEF) and heart failure mid-range ejection fraction (HFmrEF) patients. Methods: A total of 104 people consisting of HFrEF and HFmrEF patients (n=54) and healthy (n=50) subjects were included in this comparative cross-sectional study. The study took place in Gulhane Training and Research Hospital, Ankara, Turkey, between 2011 and 2013. Serum VEGF, sVEGFR-1, plasma pro-BNP analysis and transthoracic echocardiography were performed. Results: The average sVEGFR-1 level of the HFrEF and HFmrEF patients was significantly higher than the control group (0.185 +/- 0.122; 0.141 +/- 0.120; p=0.013). The average sVEGFR-1 level of the HFrEF and HFmrEF patients using beta-blocker was significantly higher than the HFrEF and HFmrEF patients not using it (p=0.015). There was a significant and positive correlation between sVEGFR-1 and N-terminal pro-brain natriuretic peptide (pro-BNP) levels in the group with HF (r=0.211, p=0.044). Conclusion: It increases awareness about the role of sVEGFR-1 in HFrEF anf HFmrEF patients and the need for further studies. Beta-blocker may have a negative effect on angiogenesis in HFrEF and HFmrEF via increasing sVEGFR-1 levels. Additionally, Pro-BNP may contribute to inhibiting angiogenesis by increasing sVEGFR-1 levels and sVEGFR-1 may be an important biomarker in HFrEF and HFmrEF.eninfo:eu-repo/semantics/openAccessArticle3910Q3Q21028103430284587WOS:000452516400010